---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-013592"
form_type: "8-K"
ticker: "BCDA"
cik: "0000925741"
company_name: "BioCardia, Inc."
filed_at: "2023-05-10T23:59:59+00:00"
generated_at: "2026-06-15T07:41:44.864758+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BioCardia Q1 2023 net loss $3.5M; adaptive FDA plan for heart failure trial submitted

## Summary
- Revenue $64K (flat YoY); net loss $3.5M vs $3.3M; cash used in ops $2.6M.
- Phase III CardiAMP HF trial: adaptive statistical analysis plan submitted to FDA Apr 26; DSMB meeting late June.
- Japan PMDA submission expected Q2 2023 for CardiAMP; roll-in cohort 2-yr survival 100%.
- BCDA-03 allogeneic HFrEF trial first patient expected Q2 2023; BCDA-04 ARDS trial start Q4 2023.
- FDA audit of quality system resulted in zero written observations.

## SEC filing metadata
- accession: 0001437749-23-013592
- form_type: 8-K
- ticker: BCDA
- cik: 0000925741
- company_name: BioCardia, Inc.
- filed_at: 2023-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/925741/000143774923013592/0001437749-23-013592-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/925741/000143774923013592/bcda20230510_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-013592
- JSON: https://secwatch.observer/filing/0001437749-23-013592.json
- Plain text: https://secwatch.observer/filing/0001437749-23-013592.txt

## Key facts
- Earnings Releases
  BioCardia, Inc. reported first quarter of 2023 results: revenue approximately $64 thousand.
  - Period: first quarter of 2023
  - Revenue: approximately $64 thousand
  - Result: reported results
  source text: CellProthera’s next clinical study, and potential early access commercialization, which could begin in 2024. First Quarter 2023 Financial Results: > Revenues were approximately $64 thousand for the three months ended March 2023, compared for approximately $60 thousand in the three months ended March 2022. > Research and development expenses increased to a
  evidence_url: https://www.sec.gov/Archives/edgar/data/925741/000143774923013592/0001437749-23-013592-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.